Avita Medical, Inc. Common Stock (RCEL) is a publicly traded Healthcare sector company. As of May 21, 2026, RCEL trades at $4.32 with a market cap of $128.95M and a P/E ratio of -2.74. RCEL moved +3.22% today. Year to date, RCEL is +24.50%; over the trailing twelve months it is -35.52%. Its 52-week range spans $3.22 to $14.16. Analyst consensus is strong buy with an average price target of $7.17. Rallies surfaces RCEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Avita Medical Q1 revenue rises 4% to $19.3M, inks $25.5M BARDA deal: Avita Medical reported Q1 revenue of $19.3 million, up 4% year-over-year and 10% sequentially, with gross margin of 81.7% and operating expenses cut 11% to $24.5 million, narrowing net loss to $10.6 million ($0.35/share). The company secured a 10-year, $25.5 million BARDA agreement and reaffirmed $80–85 million full-year revenue guidance.
| Metric | Value |
|---|---|
| Price | $4.32 |
| Market Cap | $128.95M |
| P/E Ratio | -2.74 |
| EPS | $-1.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.16 |
| 52-Week Low | $3.22 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $72.35M |
| Net Income | $-45.34M |
| Gross Margin | 81.36% |
4 analysts cover RCEL: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.17.